Boston Scientific maintained at market perform

JMP Securities analyst Robert C. Faulkner kept Boston Scientific Corp. at market perform following Abbott's (formerly Guidant) announced data from its Spirit II trial, comparing Abbott's Xience Stent to the Boston Scientific Taxus stent. Xience was superior at 0.11 mm to Taxus at 0.36 mm on the primary endpoint of "late loss." Boston Scientific will co-market the Xience stent under the name Promus. Shares of the Natick, Mass.-based pharmaceutical company were down 14 cents, or 0.81%, at $17.23 on volume of 4,761,900 shares versus the three-month running average of 10,280,500 shares. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.